Prelude Therapeutics Inc (PRLD) FinancialsPRLDPrelude Therapeutics Inc

Evaluating the bottom line, Prelude Therapeutics Incorporated maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -270.93%, while the net margin is -244.06%. These profitability ratios, combined with a Return on Equity (ROE) of -57.73%, provide a clear picture of how effectively PRLD converts its operational activities into shareholder value.

In the context of the broader market, PRLD competes directly with industry leaders such as FENC and BIOA. With a market capitalization of $436.53M, it holds a significant position in the sector. When comparing efficiency, PRLD's gross margin of 100.00% stands against FENC's 95.97% and BIOA's 100.00%. Such benchmarking helps identify whether Prelude Therapeutics Incorporated is trading at a premium or discount relative to its financial performance.

Prelude Therapeutics has shown improved financial performance with a revenue of $5.70 million for Q2 2026, compared to $0 in Q2 2025, and a significant reduction in net loss from $31.23 million to $13.92 million year-over-year.